SparingVision
PrivateLast Round
Series B
Sep 14, 2022
Total Funding Raised
$147.82M
Company Overview
SparingVision is a biotechnology company focused on developing medical therapies for Retinitis Pigmentosa, offering a drug candidate aimed at treating this common inherited retinal degeneration that can lead to blindness, thereby empowering doctors to assist patients in recovering from retinal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SparingVision Comps
Public and private peers based on sector, stage, and business model.
SparingVision Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 14, 2022 | ||||
| Series A Extension | Oct 21, 2020 | ||||
| Grant | Jul 9, 2019 | ||||
| Series A | Jul 12, 2017 |
Key People
Founding team and executive leadership
SparingVision Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Retinal Degeneration Fund | Series B |
| Programme d'Investissements d'Avenir | Series B |
| Ysios Capital | Series A Extension, Series B |
| Bpifrance | Series A Extension, Series A, Series B |
| 4Bio Capital | Series B, Series A Extension |
| Sofimac Innovation | Series A Extension |
| EIC Accelerator | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 9, 2025
Kalliopi 'Kali' Stasi appointed as the new Chief Medical Officer.
- May 19, 2025
Presented PRODYGY data and research update at ASGCT 2025.
SparingVision Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about SparingVision's valuation, stock price, and market status.
